Pendulum
Pendulum is a health infrastructure software company using Artificial Intelligence and Machine Learning to solve supply chain inefficiencies. The software forecasts needs in healthcare and other industries, and makes plans to meet demand, reducing wastage and stockouts in the process. Pendulum’s software can train itself on various qualities of data, making the software applicable to North American or European systems as well as resource-limited markets in low- and middle-income countries.
Impact Objective
Improving management of medication inventory and enabling efficient decision making at the health systems level, ultimately improving healthcare delivery for the underserved.
Website
Raydiant Oximetry
Raydiant Oximetry is a clinical stage technology platform solving for multiple unmet needs during childbirth. The company’s flagship product, Lumerah, is a non-invasive pulse oximeter designed to directly measure fetal oxygen levels during labor transabdominally. The company has also developed Daisy, a postpartum hemorrhage (PPH) device designed for use on women with planned C-sections, with the goal of preventing PPH for this category of delivering mothers. Daisy has received FDA clearance and is in the early stages of commercialization.
Impact Objective
Averting unnecessary emergency C-sections and providing treatment and prevention options for women undergoing delivery by planned C-section surgery.
Website
Sonio
Samsung Medison announced Acquisition of Sonio in May 2024.
An AI-enabled software company that provides Fetal Ultrasound Practitioners with SaaS products with superior reporting capabilities and the ability to identify pregnancy complications and fetal anomalies, including the ability to assist in the diagnosis of more than 500 potential common and rare syndromes. Sonio’s software provides real time access to expert knowledge, improving security & quality of ultrasound exams, simplifying workflows and improving productivity to allow more time with the patient.
Impact Objective
Supporting the diagnosis of pregnancy complications and fetal birth defects during ultrasound scans to begin a referral process for pregnant women requiring a higher level of care.
Website
OncoLens
OncoLens is a digital health platform and software company that provides innovative oncology care management solutions to cancer patients and healthcare providers. One of the core features of the platform is Virtual Tumor Boards, a type of telemedicine service that brings together multi-disciplinary healthcare professionals to discuss cancer diagnosis, treatment options and care management. The platform also offers physician engagement tools, clinical trial matching, and clinical decision support, and allows physicians to aggregate patient data.
Impact Objective
Improving the quality of cancer care and patient outcomes through direct deliberation in a Virtual Tumor Board conference, or through physician upskilling in low- and middle-income countries.
Website
mOm Incubators
A medical device company commercializing the mOm Essential Incubator: an innovative, high-quality, low-cost, regulatory approved infant incubator that is affordable, compact, collapsible, lightweight and provides a safe thermoregulated environment for newborns. The device operates with low power consumption and battery backup, is easy to assemble/disassemble, easy to clean and enables remote monitoring and maintenance.
Impact Objective
Preventing morbidity and mortality of neonates requiring thermoregulation in remote, underserved and conflict-affected areas.
Website
Daye
Daye is a Femtech company offering a comprehensive innovative gynecological health platform with innovating in period care products, digital tools, and diagnostic testing. They have created a Pelvic Pain Clinic to assist to assist menstruators in understanding their risk for conditions such as endometriosis and PCOS, as well as a contraception recommendation engine. Daye has also created an ecologically sound tampon platform and is leveraging the tampon as a self-collection device to test for pathogens such as HPV and STIs in the home or at a clinic without the need of a physician’s examination with the Daye Diagnostic Tampon.
Impact Objective
Improve menstrual health and advance women’s healthcare in Africa through increased access to high-quality locally manufactured menstrual care products and innovative tampon-based diagnostic platform testing for HPV as part of cervical cancer prevention and treatment programs.
Website
Axena Health
Women’s health technology firm commercializing Leva, a prescription medical device and accompanying digital therapeutic indicated for the treatment of urinary and fecal incontinence. Leva helps the user to precisely and effectively conduct pelvic floor muscle training from the privacy of their own home and in real-time using a cell phone app for 5 minutes a day for 12 weeks.
Impact Objective
Meaningful improvements for women experiencing urinary incontinence or fecal incontinence that go beyond the results of Kegel exercises alone.
Website
Oxford Cancer Analytics
OXcan has developed a biomarker discovery platform that analyzes proteomics (“proteins”) using mass spectrometry, coupled with a machine learning model, to create immunoassay panels for cancer detection based on blood “liquid biopsy” and sputum samples. OXcan’s minimally invasive liquid biopsy tests are affordable and scalable in any diagnostic facility worldwide.
Impact Objective
Enabling early, accessible, and affordable detection of lung cancer to reduce cancer mortality and improve outcomes in both high-income and underserved low-resource settings.
Website
Cardiosense
Cardiosense is a medical device company that has developed CardioTag, a wearable device that leverages non-invasive sensors and artificial intelligence to build novel cardiac monitoring capabilities. The small chest-placed sensor measures pulmonary capillary wedge pressure (PCWP), a key biomarker for detecting the escalation of heart failure. This indication allows clinicians to determine the best medication dose to manage decompensated heart failure to avoid hospitalization, and can lead to creation of a clinical decision support tool to diagnose heart failure at point of care. Cardiosense’s technology platform also includes a solution to detect pre-eclampsia, eclampsia, postpartum cardiomyopathy, and hypertension.
Impact Objective
Improving heart failure diagnosis and treatment management via access to non-invasive, timely and personalized care, especially for women with cardiovascular disease and in settings where access to cardiologists is limited. More specific detection of the heart failure that more predominately affects women will also improve the quality of care women globally receive.
Website
Bactolife
Biotechnology company launching a science-backed revolutionary category of functional proteins that neutralizes harmful metabolites and enhances gut resilience.
Impact Objective
Offering protection against gastrointestinal infections and an accessible, affordable complement to vaccination for diarrheal diseases where existing options fall short.
Website
TidalSense
Medical device company commercializing N-Tidal®, a CE-marked diagnostic for chronic obstructive pulmonary disease (COPD). The N-Tidal® device helps clinicians accurately diagnose COPD at the point of care using normal, relaxed breathing.
Impact Objective
Improvements in early and accurate COPD diagnosis for people who are disproportionately undiagnosed by current spirometry-based standards of care.
Website
Contact Us
Cross-Border Impact Ventures
661 University Avenue, MaRs Centre, West Tower, Suite 1720, Toronto, ON M5G 1M1
